Levetiracetam Prophylaxis for Seizures in Traumatic Brain Injury with Subarachnoid Hemorrhage

Preferred Anticonvulsant

• Levetiracetam is recommended as the first‑line prophylactic antiepileptic drug for patients with traumatic brain injury (TBI) and subarachnoid hemorrhage (SAH) because it has a superior tolerability profile and is associated with lower morbidity compared with phenytoin. The suggested regimen is a loading dose of 1000–1500 mg IV followed by a maintenance dose of 500–1500 mg IV or oral twice daily for up to 7 days. 1

High‑Risk Indications for Prophylaxis

• Prophylactic antiepileptic therapy should be considered in TBI patients who have any of the following high‑risk features: intracranial hemorrhage (including traumatic SAH), chronic subdural hematoma, depressed skull fracture, age > 65 years, or a prior history of epilepsy. 1

Evidence Against Routine Prophylaxis for All TBI Patients

• A systematic review of 11 clinical studies encompassing more than 2,700 patients found no clear benefit of universal seizure prophylaxis after TBI, supporting a selective‑risk approach. 1

Dosing Regimen (Loading & Maintenance)

• Loading dose: 1000–1500 mg administered intravenously as a single bolus.
• Maintenance dose: 500–1500 mg given intravenously or orally twice daily; a practical approach is 1000 mg twice daily for patients with multiple risk factors or severe SAH, and 500 mg twice daily for isolated risk factors. (Consensus guideline recommendation) 1

Duration of Prophylaxis

• Prophylaxis should not exceed 7 days unless a clinical seizure occurs; extending treatment beyond this period does not reduce the risk of later seizures and may worsen neurological outcomes. 2

Renal Adjustment (Hemodialysis)

• For patients receiving hemodialysis, an additional supplemental dose of 250–500 mg levetiracetam should be administered after each dialysis session. 3

Contraindications & Precautions

Phenytoin

• Phenytoin is associated with higher morbidity and mortality, as well as poorer cognitive outcomes, in patients with SAH; therefore it should be avoided as routine prophylaxis. Levetiracetam demonstrated fewer adverse events on the Glasgow Outcome Scale‑Extended and Disability Rating Scale compared with phenytoin. 4

High‑Dose Glucocorticoids

• High‑dose glucocorticoid therapy after severe TBI increases mortality, as shown in the CRASH trial of >10,000 patients; thus it is not recommended. 1

EEG Monitoring Recommendations

• Continuous EEG monitoring is advised for patients whose level of consciousness is disproportionately depressed relative to the severity of brain injury, as non‑convulsive seizures occur in approximately 19 % of stuporous or comatose SAH patients, typically around 18 days after hemorrhage. 5
• Specific EEG monitoring criteria include Hunt‑Hess grade ≥ 3, middle cerebral artery aneurysm location, or presence of hydrocephalus. 4

Common Pitfalls to Avoid

• Routine use of phenytoin – avoid due to higher adverse‑event profile and inferior functional outcomes. 4
• Extending prophylaxis beyond 7 days without a documented seizure – provides no additional benefit and may be harmful. 1
• Using sub‑therapeutic levetiracetam doses (e.g., 250–500 mg twice daily) – many studies suggest these doses may be insufficient for seizure prevention. (Guideline caution)
• Excessive hypotonic fluid administration – large volumes of hypotonic fluids and intravascular volume contraction should be avoided after SAH to prevent worsening cerebral edema. 5

Post-Traumatic Seizure Prophylaxis Guidelines

Indications for Prophylaxis

• The American College of Medical Guidelines recommends antiepileptic prophylaxis for high-risk traumatic brain injury patients, including those with intracranial hemorrhage, depressed skull fracture, loss of consciousness or amnesia >24 hours, age >65 years, and chronic subdural hematoma or past history of epilepsy, for a maximum of 7 days 6, 7, 8
• Prophylaxis is not routinely recommended for all traumatic brain injury patients, as overall prevention of post-traumatic seizures with antiepileptics cannot be broadly recommended based on analysis of over 2,700 patients across 11 clinical trials 7

First-Line Agent

• The guideline society recommends levetiracetam as the preferred first-line agent due to better tolerability, lack of significant drug interactions, and comparable efficacy to phenytoin, with a loading dose of 1000-1500 mg IV and maintenance of 500-1500 mg IV/PO twice daily 6

Alternative Agent

• Phenytoin remains an acceptable alternative, particularly when rapid CSF penetration is prioritized, with a loading dose of 18-20 mg/kg IV at maximum rate of 50 mg/min and maintenance of standard therapeutic dosing 6

Critical Management Principles

• The duration of prophylaxis should not exceed 7 days unless actual seizures occur, as prolonged prophylactic use is not supported by evidence and may worsen neurological outcomes 7
• Valproate should be avoided due to increased mortality in traumatic brain injury patients, and high-dose glucocorticoids should not be used after severe traumatic brain injury, as they have been associated with higher mortality rates 8

Management of Active Seizures

• Benzodiazepines, such as lorazepam, are recommended as the first-line treatment for active seizures, and levetiracetam, fosphenytoin, or valproate show equal efficacy for refractory status epilepticus 6, 7

Monitoring Considerations

• Continuous EEG monitoring should be implemented in patients with depressed mental status disproportionate to brain injury severity to detect nonconvulsive seizures, and head CT is the preferred initial imaging modality to identify acute intracranial hemorrhage or mass effect requiring urgent intervention 6, 9

Risk‑Based Antiepileptic Prophylaxis in Moderate‑to‑Severe Traumatic Brain Injury

High‑Risk Features Requiring Early Prophylaxis

Patients with any of the following should receive antiepileptic prophylaxis within the first 7 days after injury 10:

Recommended Prophylaxis Regimen and Duration

Levetiracetam is the preferred first‑line agent; prophylaxis should not exceed 7 days unless a clinical seizure occurs 10.

Evidence Against Routine (Universal) Prophylaxis

Lack of Benefit for Late Seizure Prevention

Agents to Avoid in Severe TBI

Management of Clinical Seizures

Common Pitfalls Highlighted by Evidence

All statements are supported by the cited evidence from the Anaesthesia journal (2018) and related high‑quality trials.